As part of its mission to make a dent in the sizable presbyopia market, Lenz Therapeutics has scoped out a star-studded partnership for its Vizz prescription eye drops. Sarah Jessica Parker has signed ...

LENZ Therapeutics (LENZ) has been getting attention after strong early use of its FDA approved presbyopia eye drop VIZZ and an exclusive commercialization deal with Lunatus covering several Middle ...

LENZ Therapeutics and Lunatus Marketing & Consulting FZCO recently announced an exclusive agreement for Lunatus to register and commercialize VIZZ, an FDA-approved aceclidine-based eye drop for ...

LENZ Therapeutics, Inc. shares fell ~30% after a reported adverse event with VIZZ, but I do not view this as thesis-destroying. VIZZ offers superior efficacy and duration versus competitors, yet faces ...

Jeffrey Lenz, 53, of Noblesville, Indiana, passed away peacefully on October 31, 2025, surrounded by his loved ones, following a brave battle with a glioblastoma brain tumor. He is survived by his ...

The price trend for LENZ Therapeutics, Inc. (LENZ) has been bearish lately and the stock has lost 6.3% over the past week. However, the formation of a hammer chart pattern in its last trading session ...

'Mad Money' host Jim Cramer talks Lenz Therapeutics and why he likes the stock here. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to ...

Caroline Lenz McClure passed away peacefully in Stockton on September 8, 2025. Caroline was a Stocktonian and member of a pioneer agricultural family. She was the daughter of Howard Oliver Lenz and ...

Have computer programmers innovated themselves out of a job? That’s the fear driving theories that AI will remove the need for humans who can write computer code. Today's most sophisticated large ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past efforts by other drug developers have mostly been unsuccessful. The ...

On Thursday, the U.S. Food and Drug Administration approved LENZ Therapeutics, Inc.’s (NASDAQ:LENZ) VIZZ (aceclidine ophthalmic solution, previously known as LNZ100) 1.44%, the first and only ...